Citi analyst Yigal Nochomovitz raised his price target for Mirati Therapeutics to $77 but keeps a Neutral rating on the shares. The analyst says he continues to have “well above-average” expectations for Mirati’s KRAS G12C inhibitor MRTX849, “even taking the unusual step” of raising his probability of success to 25% ahead of any Phase 1 data. However, the stock is now up 70% year-to-date and is already ascribing a ~25% probability of success to MRTX849, Nochomovitz tells investors in a research note.
https://thefly.com/landingPageNews.php?id=2873571
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.